Breast cancer | Carboplatin-treated lung cancer | Cisplatin-treated lung cancer | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
All | Older 5-HT3RAs | Palonosetron | P | All | Older 5-HT3RAs | Palonosetron | P | All | Older 5-HT3RAs | Palonosetron | P | |
N | 3,606 | 1,742 | 1,864 | 4,497 | 2,691 | 1,806 | 1,154 | 764 | 390 | |||
Type of payer (%) | NS | NS | NS | |||||||||
Commercial | 3,321 (92.1) | 1,592 (91.4) | 1,729 (92.8) | 3,632 (80.8) | 2,149 (79.9) | 1,483 (82.1) | 971 (84.1) | 638 (83.5) | 333 (85.4) | |||
Public | 167 (4.6) | 87 (5.0) | 80 (4.3) | 715 (15.9) | 448 (16.7) | 267 (14.8) | 121 (10.5) | 81 (10.6) | 40 (10.3) | |||
Self-insured | 100 (2.8) | 54 (3.1) | 46 (2.5) | 134 (3.0) | 84 (3.1) | 50 (2.8) | 55 (4.8) | 39 (5.1) | 16 (4.1) | |||
Unknown | 18 (0.5) | 9 (0.5) | 9 (0.5) | 16 (0.4) | 10 (0.4) | 6 (0.3) | 7 (0.6) | 6 (0.8) | 1 (0.3) | |||
Type of plan (%) | <0.0001 | <0.0001 | NS | |||||||||
HMO | 813 (22.6) | 434 (24.9) | 379 (20.3) | 1,071 (23.8) | 734 (27.3) | 337 (18.7) | 272 (23.6) | 182 (23.8) | 90 (23.1) | |||
Indemnity | 320 (8.9) | 136 (7.8) | 184 (9.9) | 854 (19.0) | 499 (18.5) | 355 (19.7) | 170 (14.7) | 112 (14.7) | 58 (14.9) | |||
PPO | 1,742 (48.3) | 792 (45.5) | 950 (51.0) | 1,982 (44.1) | 1,114 (41.4) | 868 (48.1) | 551 (47.8) | 360 (47.1) | 191 (49.0) | |||
POS | 556 (15.4) | 316 (18.1) | 240 (12.9) | 462 (10.3) | 278 (10.3) | 184 (10.2) | 120 (10.4) | 77 (10.1) | 43 (11.0) | |||
Other | 175 (4.9) | 64 (3.7) | 111 (6.0) | 128 (2.9) | 66 (2.5) | 62 (3.4) | 41 (3.6) | 33 (4.3) | 8 (2.1) | |||
Pharmacy benefit (%) | 0.0008 | <0.0001 | NS | |||||||||
No | 700 (19.4) | 300 (17.2) | 400 (21.5) | 1,229 (27.3) | 656 (24.4) | 573 (31.7) | 246 (21.3) | 151 (19.8) | 95 (24.4) | |||
Yes | 2,372 (65.8) | 1,198 (68.8) | 1,174 (63.0) | 2,809 (62.5) | 1,769 (65.7) | 1,040 (57.6) | 761 (65.9) | 518 (67.8) | 243 (62.3) | |||
Unknown | 534 (14.8) | 244 (14.0) | 290 (15.6) | 459 (10.2) | 266 (9.9) | 193 (10.7) | 147 (12.7) | 95 (12.4) | 52 (13.3) |